According to a recent press release, Astellas and Seagen have teamed up to develop a combined treatment for urothelial cancer in patients who are ineligible to receive cisplatin chemotherapy. The new...
Abbott recently announced that they had been granted Breakthrough Device Designation by the FDA, which allows them to investigate the use of deep brain stimulation (DBS) in managing severe...
According to the Cleveland Clinic, approximately 1 in 10 people in the United States have liver disease. Current diagnostic methods for liver disease have proven ineffective in early diagnosis. Oncoustics is one of many companies looking...
A recent statement by Verve Therapeutics announced the start of the phase 1b clinical trial on heterozygous familial hypercholesterolemia (HeFH) in New Zealand. This announcement highlighted the first...
The FDA recently approved Skyrizi as a treatment for moderate to severely active Crohn’s disease. Crohn’s disease is an inflammatory bowel disease (IBD) with many painful symptoms that can...
FDA recently lifted the clinical hold on Gilead’s investigational new drug application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis...
FDA recently approved Eli Lilly and Company’s Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes as an addition to diet and...
Bristol Myers Squibb recently announced that its severe plaque psoriasis treatment, deucravacitinib, elicited durable efficacy and a consistent safety profile in adult...
Roche’s Global Access Program and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, recently partnered to build and strengthen diagnostic capacity and pandemic preparedness in...
The Janssen Pharmaceutical Companies of Johnson & Johnson recently terminated its collaboration with Bavarian Nordic, which developed potential vaccines against the hepatitis B virus and human...
Pfizer recently presented real-world evidence demonstrating a significant benefit for patients treated with Ibrance (palbociclib) combined with an aromatase inhibitor (AI) compared to AI...
Novartis recently announced that its IgG4 anti-PD-1 monoclonal antibody, tislelizumab, plus chemotherapy, significantly improved overall survival (OS) compared to chemotherapy in esophageal...
Gilead and Dragonfly Therapeutics recently collaborated to advance several of Dragonfly’s novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation...
Eli Lilly and Company recently announced that patients in a Phase 3 trial who received its obesity drug, tirzepatide, lost up to 22.5% of their body weight.
The SURMOUNT-1 clinical trial...
FDA recently approved AstraZeneca’s Ultomiris to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
The agency based the...
AstraZeneca recently announced plans to open a new drug research and development site at the heart of Cambridge, MA, for itself and Alexion’s new corporate headquarters.
The strategic center...
FDA recently accepted AstraZeneca’s biologics license application (BLA) for its anti-CTLA4 antibody, tremelimumab, supporting the indication of a single primary dose of the drug added to Imfinzi...
Pfizer and Valneva recently reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
The Phase 2 trial, VLA15-221, is the first clinical study with VLA15 that enrolled...
Sandoz recently launched its generic drug combination eyedrop, brimonidine tartrate/ timolol maleate ophthalmic solution 0.2%/0.5%, to lower eye pressure in patients with ocular...
FDA recently accepted the New Drug Application (NDA) for GSK’s daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to treat patients with anemia of chronic kidney...
